Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Hum Mutat ; 43(2): 228-239, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34923708

RESUMEN

The recent discovery of TRPV6 as a pancreatitis susceptibility gene served to identify a novel mechanism of chronic pancreatitis (CP) due to Ca2+ dysregulation. Herein, we analyzed TRPV6 in 81 probands with hereditary CP (HCP), 204 probands with familial CP (FCP), and 462 patients with idiopathic CP (ICP) by targeted next-generation sequencing. We identified 25 rare nonsynonymous TRPV6 variants, 18 of which had not been previously reported. All 18 variants were characterized by a Ca2+ imaging assay, with 8 being identified as functionally deficient. Evaluation of functionally deficient variants in the three CP cohorts revealed two novel findings: (i) functionally deficient TRPV6 variants appear to occur more frequently in HCP/FCP patients than in ICP patients (3.2% vs. 1.5%) and (ii) functionally deficient TRPV6 variants found in HCP and FCP probands appear to be more frequently coinherited with known risk variants in SPINK1, CTRC, and/or CFTR than those found in ICP patients (66.7% vs 28.6%). Additionally, genetic analysis of available HCP and FCP family members revealed complex patterns of inheritance in some families. Our findings confirm that functionally deficient TRPV6 variants represent an important contributor to CP. Importantly, functionally deficient TRPV6 variants account for a significant proportion of cases of HCP/FCP.


Asunto(s)
Canales de Calcio , Pancreatitis Crónica , Canales Catiónicos TRPV , Canales de Calcio/genética , Proteínas Portadoras/genética , Predisposición Genética a la Enfermedad , Humanos , Mutación , Pancreatitis Crónica/genética , Canales Catiónicos TRPV/genética , Inhibidor de Tripsina Pancreática de Kazal/genética
2.
Clin J Gastroenterol ; 11(5): 424-427, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29680982

RESUMEN

BACKGROUND: Dietary supplementation of arginine has been used by numerous world-class athletes and professional bodybuilders over the past 30 years. L-Arginine indeed enhances muscular power and general performance via maintaining ATP level. However, L-arginine is also known to induce acute pancreatitis in murine models. CASE REPORT: We report the case of young man presenting with upper abdominal pain and increased serum lipase levels. Contrast-enhanced computed tomography confirms a mild acute pancreatitis. Common etiologies have been ruled out and toxicological anamnestic screening reveals the intake of protein powder. This is, to the best of our knowledge, the second case in human of arginine-induced acute pancreatitis. CONCLUSION: This case report suggests that every patient presenting with acute pancreatitis without obvious etiology should be evaluated for the intake of toxics other than alcohol, including L-arginine.


Asunto(s)
Arginina/efectos adversos , Suplementos Dietéticos/efectos adversos , Pancreatitis/inducido químicamente , Dolor Abdominal/etiología , Enfermedad Aguda , Adulto , Humanos , Masculino , Pancreatitis/diagnóstico
3.
Gastroenterology ; 150(4): 903-10.e8, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26764182

RESUMEN

BACKGROUND & AIMS: Severe alcoholic hepatitis (AH) is a life-threatening disease for which adequate oral nutritional support is recommended. We performed a randomized controlled trial to determine whether the combination of corticosteroid and intensive enteral nutrition therapy is more effective than corticosteroid therapy alone in patients with severe AH. METHODS: We enrolled 136 heavy consumers of alcohol (age, 18-75 y) with recent onset of jaundice and biopsy-proven severe AH in our study, performed at 18 hospitals in Belgium and 2 in France, from February 2010 through February 2013. Subjects were assigned randomly (1:1) to groups that received either intensive enteral nutrition plus methylprednisolone or conventional nutrition plus methylprednisolone (controls). In the intensive enteral nutrition group, enteral nutrition was given via feeding tube for 14 days. The primary end point was patient survival for 6 months. RESULTS: In an intention-to-treat analysis, we found no significant difference between groups in 6-month cumulative mortality: 44.4% of patients died in the intensive enteral nutrition group (95% confidence interval [CI], 32.2%-55.9%) and 52.1% of controls died (95% CI, 39.4%-63.4%) (P = .406). The enteral feeding tube was withdrawn prematurely from 48.5% of patients, and serious adverse events considered to be related to enteral nutrition occurred in 5 patients. Regardless of group, a greater proportion of patients with a daily calorie intake less than 21.5 kcal/kg/day died (65.8%; 95% CI, 48.8-78.4) than patients with a higher intake of calories (33.1%; 95% CI, 23.1%-43.4%) (P < .001). CONCLUSIONS: In a randomized trial of patients with severe AH treated with corticosteroids, we found that intensive enteral nutrition was difficult to implement and did not increase survival. However, low daily energy intake was associated with greater mortality, so adequate nutritional intake should be a main goal for treatment. ClinicalTrials.gov number: NCT01801332.


Asunto(s)
Corticoesteroides/uso terapéutico , Nutrición Enteral , Hepatitis Alcohólica/terapia , Metilprednisolona/uso terapéutico , Adolescente , Corticoesteroides/efectos adversos , Adulto , Anciano , Bélgica , Biopsia , Terapia Combinada , Ingestión de Energía , Nutrición Enteral/efectos adversos , Nutrición Enteral/mortalidad , Femenino , Francia , Hepatitis Alcohólica/diagnóstico , Hepatitis Alcohólica/mortalidad , Hepatitis Alcohólica/fisiopatología , Humanos , Análisis de Intención de Tratar , Masculino , Metilprednisolona/efectos adversos , Persona de Mediana Edad , Evaluación Nutricional , Estado Nutricional , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...